Statistical Methods
White paper by Luce and O'Hagan from “The Bayesian Initiative”, formed to explore the extent to which formal Bayesian statistical analysis can and should be incorporated into the field of HEOR for the purpose of assisting rational health care decision-making.
The purpose of this article is to briefly outline some of the SPC tools available for monitoring a health care process with corresponding references to their application. (Source: Stephen Schmaltz, PhD, National Measures Clearinghouse, Nov 2009)
Thought-provoking article suggesting that evidence-based medicine today has become evidence-burdened instead. (Source: Hegde, Mangalorean.com, Nov. 2009)
Wonderful primer that makes the subject of bayesian statistics understandable, relevant, and interesting, by Luce and O'Hagan.
Presentation at ISPOR Europe, Nov. 2011, by Olivier Ethgen MSc, PhD, Associate Professor of Health Economics, Department of Public Health Sciences, University of Liege, Liege, Belgium
Confirmatory Factor Analysis e-course from Center for Statistical Information introduces confirmatory factor analysis (CFA) using AMOS. As such, it is a basic and applied introduction into latent variable modeling. The module starts with the theoretical ideas behind this method but quickly delves into applied aspects of conducting CFAs. Most of the module is spent on how to create, run, and interpret CFAs. Participants will be provided with demonstrations and trainings that guide you throug
Provides readers with insights into the practical use of factor analysis through clear and readable text with illustrative examples. To complement the edifying book, they also provide a new web-based tool that responds to the important need to document the replicability of the factor solution.
The Disease Management Purchasing Consortium (DMPC) and Zenger Analytics have completed a mathematical proof to address the question of valid outcomes methodologies for disease management, wellness, medical home and other population-based care management programs for which outcomes are calculated on a pre/post basis.(Source: Managed Healthcare Executive E-News, Al Lewis)
First in a series of articles to discuss how to use evidence to arrive at reliable scientific conclusions? (Source Steven Novella, Science-Based Medicine, Nov. 18, 2009)
Performs customized calculations of the value of new drugs, medical devices and other therapeutic interventions. The Model links cost and utilization data from large patient care databases to published clinical data specific to new drugs, classes of drugs, diagnostics, medical technologies, or a combination of drugs and technologies used to treat a specific disease.
Provides Vitalnet software for analyzing and disseminating health statistics/data sets to run on desktop or web browser. Makes tables, charts, maps, stats.
Improved forecast quality through ’deep strategy’ brought on by dynamic scenario planning, the best way to understand and control corporate risks
The Program in Cost-Effectiveness and Outcomes provides up-to-date data for researchers and provides a forum for students and researchers wishing to share ideas and solve problems specific to cost-effectiveness analysis. A generic life table is available for converting risk ratios to changes in life expectancy.
Consensus documents on key outcomes research methods. ISPOR convenes experts in outcomes research to develop guidance for researchers on contentious outcomes research methods.
The AHRQ QIs are measures of quality associated with processes of care that
occurred in an outpatient or an inpatient setting.
How to produce national and regional estimates by weighing the unweighted HCUP data (e-news, Issue #24).
Presentation at ISPOR Europe, Nov. 2011, by Andreas Gerber, PhD, MD, Head, Department of Health Economics, Institute of Quality and Efficiency in Health Care (IQWiG), Cologne, Germany
Presentation at ISPOR Europe, Nov. 2011, by Károly Kulich, PhD, PRO Expert, Novartis Pharmaceuticals Corporation, Basel, Switzerland
Presentation at ISPOR Europe, Nov. 2011, by Karl C. Claxton, MSc, DPhil, Professor & Senior Research Fellow, Centre for Health Economics, University of York, Heslington, York, UK
Presentation at ISPOR Europe, Nov. 2011, by Stuart Peacock, DPhil, Associate Professor, University of British Columbia and Co-Director, Canadian Centre for Applied Research in Cancer Control (ARCC), Vancouver, BC, Canada
NPC Chief Science Officer Dr. Robert Dubois suggested that tying coverage or clinical guidelines to "average" results may have untoward effects on health for individual patients, according to new research he presented on June 6 at the Agency for Healthcare Research and Quality's (AHRQ) Methods Symposium.
Editorial in JMCP, May 2010 "It Depends on What “Mean” Means: Averaging Versus Event Patterning in Analyses of Administrative Claims Data" (Source: AMCP, May 2010)
We saw in out last post that we always want to reduce variability in our data. Stratification is used as a means of controlling sources variation in data as it potentially relates to the outcome. When we combine stratification with blocking, we get a Randomized Block Design.(Source:Michael O'Brien, BA, MS, Statistical Consultant at Aestus Therapeutics, Inc.)
Presentation at ISPOR Europe, Nov. 2011, by Alison Bourke, MSc, MRPharmS, Managing Director, UK, Cegedim Strategic Data Medical Research Ltd., London, UK
MEPSnet is a collection of analytical tools that operate on Medical Expenditure Panel Survey (MEPS) data in the Household and Insurance component. Available online, MEPSnet is quick and easy to use, allowing even novice users the ability to generate national estimates in a few seconds.
Presentation at ISPOR Europe, Nov. 2011, by Heiner C. Bucher, MD, MPH, Director, Institute for Clinical Epidemiology & Biostatistics (CEB), University Clinic Basel, Basel, Switzerland
Presentation at ISPOR Europe, Nov. 2011, by Stefan Lange, MD, PhD, Deputy Director, Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany
Presentation at ISPOR Europe, Nov. 2011 by Sonya Eremenco, MA, e-PRO Manager, United BioSource Corporation, Bethesda, MD, USA
ISPOR Special Interest Group & Task Force Forum
Excellent review of the literature, good research practices, etc. in pdf file.
There is increasing interest in deploying and publicly reporting a risk-adjusted measure of mortality as a quality indicator of hospital system-level performance. The presentations provided here are from a November 2008 meeting to discuss relative merits, interpretation, attributes, and potential uses related to mortality measures.
Presentation at ISPOR Europe, Nov. 2011 by Ben A. Van Hout, PhD, Professor of Health Economics, School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
Multilevel Modeling II using repeated measures data e-course from The Center for Statistical Instruction. The module briefly introduce the logic of the method (including when and why to use it). The module uses SAS but prior knowledge of SAS is not required because templates of necessary code are provided so that only minimal alterations are required.
Multilevel Modeling using repeated measures data e-course from The Center for Statistical Information. The module briefly introduces the logic of the method (including when and why to use it). The module uses SAS but prior knowledge of SAS is not required because templates of necessary code are provided so that only minimal alterations are required. Numerous demonstrations and training exercises running the models in SAS and interpreting the output are provided.
Presentation at ISPOR Europe, Nov. 2011 by Andrew Lloyd, DPhil, Vice President, Oxford Outcomes, Oxford, UK
Presentation at ISPOR Europe, Nov. 2011, by Jack Ishak, PhD, Director, Biostatistics & Senior Research Scientist, United BioSource Corporation, Dorval, QC, Canada
Interactive program for performing power and sample size calculations that may be downloaded for free. It can be used for studies with dichotomous, continuous, or survival response measures.
Recommendations on Evidence Needed to Support Measurement Equivalence ISPOR EPRO Good Research Practices Task Force. Presentation at ISPOR Europe, Nov. 2011 by Stephen Joel Coons, PhD, Chad J. Gwaltney, PhD, Ron D. Hays, PhD, J. Jason Lundy, MS, Jeff A. Sloan, PhD, Dennis A. Revicki, PhD, William R. Lenderking, PhD, David Cella, PhD, Ethan Basch, MD, MSc on behalf of the ISPOR ePRO Task Force
Debate over the proper use of racial and ethnic categories in biomedical research has raged in recent years. With the Human Genome Project showing that human beings are overwhelmingly alike genetically, exhibiting more genetic variation within supposed "races" than between them, many have come to doubt the scientific utility of such categories. Yet federal authorities use Directive 15 from the Office of Management and Budget (OMB) to mandate the continued use of such categories in research.(Source:Wolf, Susan, Journal of Law, Medicine & Ethics, Vol.34,No.3,pg. 483-559)
Responsiveness was included as an intrinsic goal in the health systems performance framework because the way people are treated when they come into contact with the system can improve or reduce their well-being independently of health outcomes.
We review statistical methods for analysing healthcare resource use and costs, their ability to address skewness, excess zeros, multimodality and heavy right tails, and their ease for general use. We aim to provide guidance on analysing resource use and costs focusing on randomised trials, although methods often have wider applicability. (Source:Health Economics,Volume 20, Issue 8, pages 897-916, August 2011 Borislava Mihaylova, Andrew Briggs, Anthony O'Hagan and Simon G. Thompson)
Free download from SAS
Presentation at ISPOR Europe, Nov. 2011 by Jack Ishak, PhD, Director, Biostatistics & Senior Research Scientist, United BioSource Corporation, Dorval, QC, Canada
The Academy of Managed Care Pharmacy (AMCP) has identified major benchmarking data publications that are commonly used within the managed care environment. Source: Academy of Managed Care Pharmacy)
Download documents, book chapters, and practice questions for Statistics and Evidence Based Medicine for Exams.
Graphic showing number needed to treat to get a benefit for various drugs
Four major content areas for which abstracts were solicited from scientists across the United States included: (1) study design, (2) data collection, (3) statistics and analytic methods, and (4) policy issues and applications. The symposium proceedings are published in a supplement to the June 2010 issue of the journal Medical Care. A printed copy of the supplement is available free of charge through the AHRQ Publications Clearinghouse.
Alongside the emergence of many technology-based ways of capturing PRO data is the need to assure measurement equivalence across and among these methods and modes of administration (Coons et al., 2009). This becomes especially important if multiple methods or modes are utilized within a single trial. For the purpose of this paper, we have adopted the distinction made in the PRO Guidance between PRO instrument administration modes and data collection methods.
The objective of this paper is to examine how well the QALY captures the health gains generated by cancer treatments, with particular focus on the methods for constructing QALYs preferred by the UK National Institute for Health and Clinical Excellence (NICE).
